Covenant Partners, LLC Neurocrine Biosciences Inc Transaction History

Covenant Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 19, 2023	BUY	$94.11 - $123.02 $26,539 - $34,691	282 Added 14.51%	2,225 $225,000
Q4 2022 Feb 17, 2023	BUY	$106.72 - $127.06 $207,356 - $246,877	1,943 New	1,943 $232,000
Q2 2021 Aug 02, 2021	SELL	$89.43 - $102.27 $183,778 - $210,164	-2,055 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$87.57 - $119.4 $179,956 - $245,367	2,055 New	2,055 $200,000
Q4 2020 Feb 10, 2021	SELL	$86.91 - $108.33 $193,374 - $241,034	-2,225 Closed	0 $0
Q3 2020 Nov 10, 2020	BUY	$96.16 - $135.15 $213,956 - $300,708	2,225 New	2,225 $214,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Covenant Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Covenant Partners, LLC with notifications on news.